Cutaneous vs Systemic Lupus: What is the Difference?
At a Glance
Cutaneous lupus primarily affects the skin, while systemic lupus erythematosus (SLE) can affect internal organs. Most people with skin lupus do not develop systemic lupus. Your risk depends heavily on your specific skin lupus subtype and can be monitored through regular blood and urine tests.
In this answer
4 sections
If you have been diagnosed with cutaneous lupus, you are likely wondering if it will eventually turn into systemic lupus. The short answer is: for most people—though it depends on your specific subtype—it will not [1]. Cutaneous lupus erythematosus (CLE) is a type of lupus that primarily affects the skin, whereas systemic lupus erythematosus (SLE) is a disease that can affect multiple internal organs, such as the kidneys, heart, and joints [2]. While anyone with skin lupus has a small inherent risk of developing systemic lupus, the actual rate of this happening is lower than previously believed [1].
Understanding the Two Conditions
To understand your risk, it helps to know how doctors categorize lupus:
- Cutaneous lupus erythematosus (CLE): This refers to lupus that is confined to the skin. It causes rashes, sores, or hair loss [2].
- Systemic lupus erythematosus (SLE): This is the more recognized form of lupus. “Systemic” means it involves the entire body. In SLE, the immune system can attack internal organs, causing joint pain, severe fatigue, kidney issues, and other internal inflammation [2][3].
Types of Skin Lupus and Your Risk
Doctors categorize skin lupus into three main subtypes [4][2]. Your specific subtype plays a major role in determining your risk of developing systemic lupus:
- Chronic Cutaneous Lupus (CCLE): The most common form of this is Discoid Lupus Erythematosus (DLE), which causes disc-shaped, scarring rashes often on the scalp and face [5][6]. The vast majority (over 90%) of people with isolated discoid lupus do not go on to develop systemic lupus [7][5].
- Subacute Cutaneous Lupus (SCLE): This type typically causes non-scarring, ring-shaped or scaly rashes on sun-exposed areas of the body. People with SCLE have a slightly higher chance of also having or developing systemic lupus. Studies show about 28% of patients diagnosed with SCLE have an associated systemic autoimmune disease like SLE [8].
- Acute Cutaneous Lupus (ACLE): This type is famous for the “butterfly rash” across the cheeks and nose. ACLE is very closely tied to systemic lupus. In fact, if you have acute cutaneous lupus, it is often an indicator of active systemic lupus [9].
What Increases the Risk of Progression?
While most isolated skin lupus stays in the skin, doctors look for specific clues that suggest a higher risk of it transitioning to systemic lupus [4].
Factors you cannot control:
- Having widespread discoid lupus lesions across the body, rather than just in one spot [10][5].
- Having multiple different types of skin lupus at the same time (overlapping subtypes) [10][11].
- Positive results on specific blood tests, such as antinuclear antibodies (ANA) (a marker of autoimmune activity in your blood) [5]. Note: A positive ANA test does not guarantee you have or will develop systemic lupus. It is just one piece of the puzzle, and many healthy people or people with skin-only lupus have positive ANA results.
- Being female, which generally carries a higher risk for all forms of lupus [5].
Factors you CAN control to protect your health:
You are not powerless. You can actively manage your condition and potentially reduce your risk of flares by:
- Strict Sun Protection: Ultraviolet (UV) light is a well-documented trigger for all types of lupus. Daily use of broad-spectrum sunscreen (SPF 50+) and wearing UPF-protective clothing is essential.
- Quitting Smoking: Smoking is known to trigger lupus flares and significantly decreases the effectiveness of antimalarial medications often prescribed to treat skin lupus.
The Importance of Monitoring
The risk of transitioning from cutaneous to systemic lupus is highest in the first three to five years after your diagnosis, making continuous monitoring crucial during this time [12][1]. This usually means working closely with both a dermatologist (a skin specialist) and a rheumatologist (an autoimmune and joint specialist).
Your care team will monitor you through:
- Routine Blood Work: Checking for specific autoantibodies like ANA or anti-dsDNA (another specific antibody strongly linked to systemic lupus) [4].
- Urinalysis: Testing your urine once a year is standard practice to check for kidney involvement [13]. It is extremely important to do this even if you feel perfectly healthy, because early kidney inflammation often causes absolutely no physical symptoms.
- Symptom Tracking: Pay attention to any new physical changes, especially joint pain, extreme fatigue, chest pain when breathing, or persistent fevers.
Remember, an isolated skin lupus diagnosis is not a guarantee of future systemic disease. Regular check-ups help ensure that if systemic lupus does develop, it is caught and treated as early as possible.
Common questions in this guide
What is the difference between cutaneous lupus and systemic lupus?
Will my cutaneous lupus eventually turn into systemic lupus?
What tests are used to monitor skin lupus for systemic progression?
How can I lower my risk of skin lupus flaring?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific subtype of cutaneous lupus do I have, and how does that affect my risk of developing systemic lupus?
- 2.Based on my blood work and skin symptoms, should I have a baseline evaluation with a rheumatologist?
- 3.Which baseline blood tests and urine tests should we run today to check for any systemic involvement?
- 4.How often should we re-check my blood and urine over the next three to five years?
- 5.Are my skin lesions considered localized or generalized, and does that change my monitoring plan?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (13)
- 1
Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark.
Petersen MP, Möller S, Bygum A, et al.
Lupus 2018; (27(9)):1424-1430 doi:10.1177/0961203318777103.
PMID: 29788808 - 2
Current Insights in Cutaneous Lupus Erythematosus Immunopathogenesis.
Garelli CJ, Refat MA, Nanaware PP, et al.
Frontiers in immunology 2020; (11()):1353 doi:10.3389/fimmu.2020.01353.
PMID: 32714331 - 3
Unveiling Ocular Manifestations in Systemic Lupus Erythematosus.
Musa M, Chukwuyem E, Ojo OM, et al.
Journal of clinical medicine 2024; (13(4)) doi:10.3390/jcm13041047.
PMID: 38398361 - 4
Cutaneous lupus erythematosus - from pathogenesis to targeted therapy.
Klein B, Billi AC, Abernathy-Close L, Kahlenberg JM
Nature reviews. Rheumatology 2025; (21(12)):703-718 doi:10.1038/s41584-025-01318-6.
PMID: 41204012 - 5
Persistent red and swollen eyelids.
Maya Y, Tashimo A, Ota M
Lancet (London, England) 2018; (392(10157)):1552 doi:10.1016/S0140-6736(18)32327-4.
PMID: 30496061 - 6
Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus.
Fetter T, Braegelmann C, de Vos L, Wenzel J
Frontiers in medicine 2022; (9()):915828 doi:10.3389/fmed.2022.915828.
PMID: 35712102 - 7
A secondary discoid lupus erythematosus induced by scald of edible oil: An illustration of Koebner phenomenon.
Ji YZ, Mei XL, Wei FL, et al.
Journal of cosmetic dermatology 2020; (19(7)):1699-1701 doi:10.1111/jocd.13189.
PMID: 31660688 - 8
Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics, Disease Associations, Treatments, and Outcomes in a Series of 90 Patients at Mayo Clinic, 1996-2011.
Alniemi DT, Gutierrez A, Drage LA, Wetter DA
Mayo Clinic proceedings 2017; (92(3)):406-414 doi:10.1016/j.mayocp.2016.10.030.
PMID: 28185656 - 9
The role of TNF-α as a potential marker for acute cutaneous lupus erythematosus in patients with systemic lupus erythematosus.
Jinshan Z, Yong Q, Fangqi C, et al.
The Journal of dermatology 2024; (51(11)):1481-1491 doi:10.1111/1346-8138.17355.
PMID: 38963308 - 10
Epidemiology of Isolated Cutaneous Lupus Erythematosus in the Multiethnic Population of Reunion Island: A Retrospective Multicenter Study.
Maillet M, Tounkara BS, Vagner D, et al.
The Journal of rheumatology 2025; (52(3)):251-256 doi:10.3899/jrheum.2024-0661.
PMID: 39617408 - 11
Systemic lupus erythematosus is a risk factor for having multiple subtypes of cutaneous lupus erythematosus.
Lu G, Brown LS, Chong BF
Lupus 2025; (34(2)):181-186 doi:10.1177/09612033241311335.
PMID: 39707863 - 12
[Lupus erythematosus].
Strunz PP, Schmalzing M, Goebeler M, Schmieder A
Dermatologie (Heidelberg, Germany) 2025; (76(9)):582-600 doi:10.1007/s00105-025-05554-5.
PMID: 40888883 - 13
Risk factors for development of systemic lupus erythematosus in patients with cutaneous lupus: a retrospective review.
Murphy B, McCourt C, O'Kane D
Clinical and experimental dermatology 2019; (44(2)):e26-e27 doi:10.1111/ced.13802.
PMID: 30280410
This page is for informational purposes only and does not replace professional medical advice. Always consult your dermatologist or rheumatologist regarding your specific lupus diagnosis, monitoring plan, and risk factors.
Get notified when new evidence is published on Systemic lupus erythematosus.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.